

- c-abl* gene mutations, 83e-7
- Cabozantinib  
 action and targets of, 102e-5t, 103e-18t  
 adverse effects of, 103e-18t  
 for lung cancer, 521  
 for medullary thyroid carcinoma, 234z
- Cachectic myopathy, 1784
- Cache valley virus, 1308t
- Cachexia (chronic disease-related malnutrition), 459-460, 1504
- CACNA1 gene mutations, 465e-2, 2589, 2629
- CAD. *See* Coronary artery disease (CAD)
- CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), 441e-18f, 2568, 2608
- Cadherins, 102e-11f
- Cadmium exposure/poisoning, 472e-1, 472e-2t, 1692t, 1856t, 1862, 2766t
- Ca-DTPA, 263e-6t, 263e-7
- Caenorhabditis elegans*, 255e-1
- Cafe-au-lait macules/spots, 359, 360t, 426e-6
- Caffeine  
 action of, 186  
 adverse effects of, 65, 194, 254, 305, 1861  
 for hypnic headache, 2598  
 for low CSF volume headache, 110  
 for migraine, 2592t  
 overdose/poisoning with, 473e-8t, 2764t  
 for post-lumbar puncture headache, 443e-3  
 for shift-work disorder, 194  
 therapeutic range of, 2764t
- CagA protein, 1039
- CAGE questionnaire, 1992, 1992t
- CAH. *See* Congenital adrenal hyperplasia (CAH)
- Calabar swellings, 1421
- Calcification  
 of coronary arteries, 270e-4, 270e-7f, 270e-11f, 271e-2f, 1585  
 dystrophic, 363, 426e-7t, 426e-8  
 extraskelatal, 426e-7-8, 426e-7t  
 metastatic, 426e-7, 426e-7t  
 of solitary pulmonary nodule, 515
- Calcific emboli, 40e-4
- Calcific tendinitis, 2248
- Calcinosis  
 in calcium apatite deposition disease, 2236  
 in dermatomyositis, 2202  
 treatment of, 2237  
 tumoral, 426e-7t, 426e-8
- Calcinosis circumscripta, 426e-8
- Calcinosis cutis  
 clinical features of, 363, 364t, 2160f  
 metastatic, 364t  
 in systemic sclerosis, 376, 2160, 2160f
- Calcinosis universalis, 426e-8
- Calciphylaxis, 363, 1816, 1816f
- Calcipotriene, 348
- Calcitonin, **2469**  
 actions of, 2469, 2501  
 adverse effects of, 426e-4  
 for bone pain, 61  
 circulating level of, 2469  
 ectopic production of, 609t  
 for hypercalcemia, 610, 2480t, 2481  
 hypocalcemic activity of, 2469  
 in medullary thyroid carcinoma, 2341  
 for osteoporosis management/prevention, 2501  
 for Paget's disease of bone, 426e-3t, 426e-4  
 pNET secreting, 559t  
 reference values for, 2758t  
 sources of, 2469  
 as tumor marker, 473t
- Calcitonin gene(s), 2469
- Calcitonin gene-related peptide (CGRP), 88, 444e-3, 2469
- Calcitriol, 315, 1816, 2466, 2484, 2488
- Calcium  
 absorption of, 2457  
 in cardiac contraction, 265e-5f, 265e-6-7, 1563  
 in chronic kidney disease, 333e-3, 1816-1817, 1816f  
 deficiency of. *See* Hypocalcemia  
 excess of. *See* Hypercalcemia  
 extracellular, 313, 313f  
 homeostasis of, 2456-2457, 2457f, 2467  
 intake of, 2457, 2497t  
 malabsorption of, postgastroectomy, 1927  
 metabolism of, 2208, 2456-2458, 2457f  
 nephrolithiasis risk and intake of, 1867, 1870  
 osteoporosis risk and intake of, 2491  
 parenteral requirement for, 98e-5t  
 recommended intake of, 95e-3t, 2496-2497, 2496t  
 reference values for, 2758t  
 renal transport of, 332e-4f, 332e-8  
 supplements. *See* Calcium supplements  
 tolerable upper intake level of, 96e-9t  
 toxicity of, 96e-9t  
 urinary excretion of, 1867  
 in vascular smooth-muscle cell function, 265e-3-4, 265e-3f
- Calcium apatite deposition disease, 2236-2237, 2236t, 2237f
- Calcium carbonate, 1920
- Calcium channel(s)  
 cardiac, 273e-2, 273e-2f  
 muscle  
 characteristics of, 265e-3-4, 265e-3f, 462e-17f  
 disorders of, 462e-16-17, 462e-17f, 462e-17t  
 in seizure initiation, 2547
- Calcium channel blockers (CCBs)  
 adverse effects of, 326-327, 1625  
 AV conduction block, 1471t  
 edema, 253t, 1443, 1651  
 erythromelalgia, 1650  
 gingival hyperplasia, 46e-1f, 237  
 heat-related illness, 479e-1  
 lupus syndrome, 2218t  
 peripheral edema, 2392  
 SA node dysfunction, 1467t, 1469  
 secondary parkinsonism, 2611  
 urinary incontinence, 81  
 xerostomia, 241  
 aldosterone-renin ratio effects of, 2320t  
 for aortic dissection, 1641  
 drug interactions of, 42t, 2711t  
 for focal atrial tachycardia, 1479  
 for heart failure, 1513  
 for hypertension, 1624t, 1625, 1821  
 for hypertrophic cardiomyopathy, 1569  
 for inappropriate sinus tachycardia, 1477  
 for ischemic heart disease, 1589-1590, 1589t  
 metabolism of, 34t, 42  
 for NSTEMI-ACS, 1596, 1597t  
 overdose/poisoning with, 473e-9t  
 perioperative prophylactic, 54  
 for Prinzmetal's variant angina, 1589, 1598  
 for Raynaud's phenomenon, 1649, 2165  
 for supraventricular tachycardia in pregnancy, 47  
 for ventricular tachycardia, 1498
- Calcium docusate, 62t
- Calcium gluconate, 312, 315, 2739
- Calcium oxalate crystals/stones  
 in ethylene glycol poisoning, 64e-9, 1858-1859  
 renal, 62e-10f, 1866, 1868f, 1870. *See also* Nephrolithiasis
- Calcium oxalate deposition disease, 2237, 2237f
- Calcium phosphate product, elevated, 363
- Calcium phosphate stones, 1866, 1870. *See also* Nephrolithiasis
- Calcium polycarboxophil, for irritable bowel syndrome, 1970t
- Calcium pyrophosphate deposition (CPPD) disease, 372e-8t, 2235-2236, 2235t, 2236f
- Calcium-sensing receptors, 313, 372e-24t
- Calcium signaling defects, 2109
- Calcium sparks, 265e-3
- Calcium supplements  
 absorption of, 2457  
 for colorectal cancer prevention, 477-478, 539  
 in elderly, 84  
 for hyperkalemia, 312  
 for hypocalcemia, 315  
 for hypoparathyroidism, 2484  
 for osteoporosis management/prevention, 2497  
 for vitamin D deficiency, 2466
- Calcofluor white, 150e-1
- Calculation ability, assessment of, 2537
- Calculus, 46e-4f, 46e-5f, 236
- Caliciviruses. *See also* Norovirus (Norwalk virus) infections  
 characteristics of, 1285  
 gene expression and replication in, 214e-4  
 structure of, 214e-2t, 214e-3f, 1286f, 1286t
- California encephalitis virus, 1309t, 1314
- California meningoencephalitis, 1314
- Californium exposure, 263e-7
- Calor, 414f, 1753
- Caloric irrigation, 209, 1775
- Caloric needs, 95e-1, 462
- Caloric restriction, aging effects and, 85, 94e-4-6
- Calorimetry, indirect, 462
- Calretinin, 120e-2t, 120e-4, 508
- CALR gene mutations, 675
- Calsequestrin, 265e-7
- Calstabin 2, 265e-6
- Calymmatobacter granulosus*, 198e-1. *See also* Donovanosis
- CAMP factor, 969
- cAMP response-element binding protein. *See* CREB (cAMP response-element binding protein)
- Camptothecin, 103e-13
- Campylobacter* spp., 1058-1059
- Campylobacter* spp. infections, **1058**  
 clinical features of, 266t, 856t, 1059t, 1060  
 colitis, vs. IBD, 1956  
 complications of, 1060  
 diagnosis of, 150e-2t, 150e-6, 856, 1060  
 differential diagnosis of, 1060-1061  
 epidemiology of, 855t, 1059  
 food-borne, 266, 855t, 856t, 857, 1059  
 Guillain-Barré syndrome and, 2695, 2696f  
 in HIV infection, 1257  
 immunoproliferative small intestinal disease, 719  
 pathogenesis of, 1059-1060  
 prognosis of, 1061  
 treatment of, 857, 1061
- Camurati-Engelmann disease (progressive diaphyseal dysplasia), 426e-5
- Canadian Cardiovascular Society, classification of cardiovascular disease, 1581t
- Canagliflozin, 2414t
- Canakinumab, 2214, 2234
- Canasa suppositories, 1960
- c-ANCA (cytoplasmic antineutrophil cytoplasmic antibody), 377e-4, 2180
- Cancer  
 anemia in, 630  
 approach to the patient, **467**  
 chromosome abnormalities in, 83e-7, 471. *See also* Cancer genetics  
 chronic meningitis in, 909t  
 clonal origin of, 101e-1, 101e-1f  
 death and dying issues, 475  
 deaths from  
 by age, 470t  
 by race and ethnicity, 16e-1f, 470f, 471t  
 by sex, 6e-1t, 6e-2f, 467t, 469f, 470t  
 by site, 467t, 469f  
 trends in, 467, 469f  
 in United States and Britain, 56t  
 worldwide, 472f  
 definition of, 103e-1  
 depression in, 2714  
 diagnosis of, 103e-1-2, 103e-1t, 468  
 effusions in, 474  
 emergencies in  
 adrenal insufficiency, 1795  
 airway obstruction, 1794, 1794f  
 biliary obstruction, 1790  
 hemolytic-uremic syndrome, 1796-1797